78.14 0.00 (0.00%)
After hours: 5:44PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||78.00 - 79.81|
|52 Week Range||76.52 - 89.72|
|PE Ratio (TTM)||38.23|
|Forward Dividend & Yield||1.84 (2.30%)|
|1y Target Est||N/A|
Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.
MDT reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Haemonetics (HAE) expects its transfusion management business to grow at a compound annual growth rate (or CAGR) in the low to mid teens. Haemonetics has planned to opt for a key account strategy. The company aims to strengthen its worldwide presence by expanding its global sales team and partnering with other software vendors and players in this segment, like Helmer.
Moody's Investors Service, ("Moody's") revised Medtronic, Inc.'s rating outlook to stable from negative. Moody's also affirmed Medtronic's A3 senior unsecured rating and its Prime-2 commercial ...
Although Haemonetics expects the overall cell salvage market to grow at a CAGR (compound average growth rate) in the low single digits, the company is focused on significantly improving its existing product line and rapidly increasing its market share in the fastest-growing markets. The above diagram shows the global market shares of Haemonetics and its competitors Fresenius (FMS), Medtronic (MDT), and LivaNova (LIVN) in the cell salvage (or auto transfusion) business in fiscal 2017. Haemonetics has improved on its older Cell Saver product in terms of connectivity and overall programming and has launched the Cell Saver Elite platform.
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%. The hemostasis management franchise within the hospital business reported revenue of close to $19.9 million in fiscal 3Q18, a YoY rise of ~17.6%. The cell processing franchise, which is also part of the hospital business, reported revenue of close to $26.8 million in fiscal 3Q18, a YoY rise of ~3.5%.
Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18. Although the combination of the NexSys PCS device and the NexLynk software is designed to result in a completely integrated and optimal bidirectional system, NexSys PCS supports an open architecture and can work with any other donor management software (or DMS). NexLynk software, however, has been designed to work optimally with NexSys PCS, and it thus eliminates the need for the translation of data between the device and the software.
In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.
As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x. The stock has a current PE ratio of 34.9x. For the calculation of the forward PE multiple of a company, the company’s current stock price is divided by the next 12-month earnings estimates for the company. The multiple is an estimate of the potential growth of the company over the next 12 months.
A firestorm in cardiology resulted when a major NIH-funded clinical trial changed its design and moved the goalposts just before reaching completion.
Medical bills can cost hundreds of thousands of dollars in retirement, so it's important to have steady income coming in. Try these good dividend-paying stocks on for size.
Headquartered in Utica, New York, ConMed (CNMD) currently employs 3,100 people worldwide. In 4Q17, ConMed reported total sales close to $222.6 million, which represents a YoY (year-over-year) rise of ~7.9% on a CC (constant currency) basis and 9% on a reported basis, driven by the robust uptake of its products in the US and in international geographies. For fiscal 2017, ConMed reported total sales close to $796 million, which represents a YoY rise of ~4.3%, both on a CC and reported basis.
Medtronic, (MDT) presenting favorable results from the studies based on the CoreValve TAVR system might boost the top line, with increased uptake of the product.
Cash-rich businesses with sustainable and growing yields don't often go on sale, but we found 10 bargain stocks in the Morningstar US Dividend Growth Index.
On February 28, 2018, Medtronic (MDT) announced that it has entered into a partnership with LVHN (Lehigh Valley Health Network), an eight-hospital network. LVHN has a presence in seven counties in Northeastern Pennsylvania.
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.